
Week In Review: WuXi Biologics Out-Licenses 4 TCE Antibodies To GSK In $1.5 Billion Pact
Extreme Media Deals and Financings WuXi Biologics (OTCPK:WXXWY, HK: 2269) outlicensed global rights for up to four pre-clinical bi- and multi-specific TCE antibodies to GSK (GSK) in a $1.5 billion agreement (see story). TCEs are […]